Cargando…

Metastatic squamous cell carcinoma of the skin with clinical response to lapatinib

BACKGROUND: Lapatinib is a tyrosine kinase inhibitor that blocks the HER2 receptor and is typically used in the setting of metastatic breast cancer. Both ERBB2 (HER2) and ERBB3 (HER3) belong to the same family of receptor tyrosine kinases. Dimerization of these receptors leads to activation of cell...

Descripción completa

Detalles Bibliográficos
Autores principales:	Strickley, John D., Spalding, Aaron C., Haeberle, M. Tye, Brown, Timothy, Stevens, Don A., Jung, Jae
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6114032/ https://www.ncbi.nlm.nih.gov/pubmed/30181930 http://dx.doi.org/10.1186/s40164-018-0111-z

Ejemplares similares

Metastatic, Her-2 Amplified Lacrimal Gland Carcinoma with Response to Lapatinib Treatment
por: Dennie, Trevor
Publicado: (2015)

Targeted treatment of head and neck squamous-cell carcinoma: potential of lapatinib
por: Gandhi, Mitul D, et al.
Publicado: (2014)

A prospective clinical trial to assess lapatinib effects on cutaneous squamous cell carcinoma and actinic keratosis
por: Jenni, D, et al.
Publicado: (2016)

Lapatinib: the evidence for its therapeutic value in metastatic breast cancer
por: Thomson, Andrew
Publicado: (2005)

Dramatic response of refractory metastatic squamous cell carcinoma of the skin with cetuximab/pembrolizumab
por: Hober, Candice, et al.
Publicado: (2021)

Survivin in Insulin-Like Growth Factor-Induced Resistance to Lapatinib in Head and Neck Squamous Carcinoma Cells
por: Lehman, Christine E., et al.
Publicado: (2019)

Role of lapatinib in the first-line treatment of patients with metastatic breast cancer
por: Oakman, Catherine, et al.
Publicado: (2010)

Cytotoxic effect of lapatinib is restricted to human papillomavirus-positive head and neck squamous cell carcinoma cell lines
por: Fumagalli, Ingrid, et al.
Publicado: (2015)

Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases – the UK experience
por: Sutherland, S, et al.
Publicado: (2010)

Randomised Phase 2 study of lapatinib and vinorelbine vs vinorelbine in patients with HER2 + metastatic breast cancer after lapatinib and trastuzumab treatment (KCSG BR11-16)
por: Sim, Sung Hoon, et al.
Publicado: (2019)

Compromised T Cell Immunity Links Increased Cutaneous Papillomavirus Activity to Squamous Cell Carcinoma Risk
por: Johnson, Luke H., et al.
Publicado: (2022)

Real‐world data of lapatinib and treatment after lapatinib in patients with previously treated HER2‐positive metastatic breast cancer: A multicenter, retrospective study
por: Xie, Yizhao, et al.
Publicado: (2020)

The role of HGF/MET and FGF/FGFR in fibroblast-derived growth stimulation and lapatinib-resistance of esophageal squamous cell carcinoma
por: Saito, Shin, et al.
Publicado: (2015)

Lapatinib-induced mesenchymal-epithelial transition in squamous cell carcinoma cells correlates with unexpected alteration of β-catenin expression
por: UMBREIT, CLAUDIA, et al.
Publicado: (2016)

Uncommon Presentation of Metastatic Squamous Cell Carcinoma of the Skin and Treatment Challenges
por: Pandey, Anita, et al.
Publicado: (2019)

Q-TWiST analysis of lapatinib combined with capecitabine for the treatment of metastatic breast cancer
por: Sherrill, B, et al.
Publicado: (2008)

Heparanase mediates a novel mechanism in lapatinib-resistant brain metastatic breast cancer()()
por: Zhang, Lixin, et al.
Publicado: (2015)

Dual HER2 blockade with lapatinib and trastuzumab in combination with chemotherapy in metastatic gastroesophageal adenocarcinoma
por: Cheong, E. Von, et al.
Publicado: (2021)

Early relapse of inflammatory breast carcinoma treated with lapatinib and capecitabine: Ten years of complete response
por: Martin Huertas, Roberto, et al.
Publicado: (2019)

A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer
por: Rugo, Hope S., et al.
Publicado: (2011)

Targeted treatment of advanced and metastaticbreast cancer with lapatinib
por: Corkery, Brendan, et al.
Publicado: (2008)

Lapatinib as first-line treatment for muscle-invasive urothelial carcinoma in dogs
por: Maeda, Shingo, et al.
Publicado: (2022)

An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer
por: Stringer-Reasor, Erica M., et al.
Publicado: (2021)

Dual-targeting strategy using trastuzumab and lapatinib in a patient with HER2 gene amplification in recurrent metachronous metastatic gallbladder carcinoma
por: Ye, Minfeng, et al.
Publicado: (2019)

The Efficacy of Pyrotinib as a Third- or Higher-Line Treatment in HER2-Positive Metastatic Breast Cancer Patients Exposed to Lapatinib Compared to Lapatinib-Naive Patients: A Real-World Study
por: Ouyang, D. J, et al.
Publicado: (2021)

Poorly Differentiated Squamous Cell Carcinoma Arising in Tattooed Skin
por: Sarma, Deba P., et al.
Publicado: (2010)

Lapatinib, Nilotinib and Lomitapide Inhibit Haemozoin Formation in Malaria Parasites
por: de Sousa, Ana Carolina C., et al.
Publicado: (2020)

Efficacy of Lapatinib in Therapy-Resistant HER2-Positive Circulating Tumor Cells in Metastatic Breast Cancer
por: Agelaki, Sofia, et al.
Publicado: (2015)

Metastatic Squamous Cell Carcinoma of the Kidney from Cholangiocarcinoma
por: Choi, Hoon, et al.
Publicado: (2012)

Lapatinib induces autophagic cell death and inhibits growth of human hepatocellular carcinoma
por: Chen, Yu-Jen, et al.
Publicado: (2014)

Molecular effects of lapatinib in patients with HER2 positive ductal carcinoma in situ
por: Estévez, Laura G, et al.
Publicado: (2014)

CORRIGENDUM to “Dual-targeting strategy using trastuzumab and lapatinib in a patient with HER2 gene amplification in recurrent metachronous metastatic gallbladder carcinoma”
Publicado: (2020)

A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer
por: Cristofanilli, Massimo, et al.
Publicado: (2012)

Metastatic Penile Squamous Cell Carcinoma Responsive to Enfortumab Vedotin
por: Fahey, Catherine C., et al.
Publicado: (2023)

Clinical and experimental aspects of squamous carcinoma of the skin.
por: Carter, R. L.
Publicado: (1973)

Tracheal squamous cell carcinoma (SCC) metastatic to the skin in a patient on a checkpoint inhibitor
por: Cassler, Nicole M., et al.
Publicado: (2015)

Zosteriform skin metastasis caused by retrograde lymphatic migration of metastatic squamous cell lung carcinoma
por: Maki, Yohei, et al.
Publicado: (2021)

Efficacy and Tolerability of Lapatinib in the Management of Breast Cancer
por: Rana, Punam, et al.
Publicado: (2012)

Development of the Rat Model of Lapatinib-Induced Diarrhoea
por: Bowen, Joanne M.
Publicado: (2014)

Lapatinib-induced acute generalized exanthematous pustulosis
por: Lakshmi, Chembolli, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_a57899uj1chprnp8u4vsllkon3